CNBX
OQB CNBX Pharmaceuticals Inc$0.0001 ↓ -0.0000 (-33.33%) Trading Down from the previous close of $0.0002, and at the day’s high of $0.0001
- YTD change
- -75.00%
- vs 20-day SMA
- -10.95%
- vs 200-day SMA
- -55.66%
Price ranges
Price & Performance
+0.00 (+100.00%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 100.0% away from all-time highs of $5.5000
- CNBX is down 75% since the beginning of the year
- CNBX is down 71% over the past 12 months
- CNBX is down 29% over the past 1 month
- 0% of all CNBX investors are betting against CNBX
CNBX reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -50.0%.
- Previous minute
- +$0.0000
- Last hour
- +$0.0000
- Last 5 days
- +0.00%
- vs 8-day SMA
- -16.23%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
CNBX Pharmaceuticals, Inc. is a clinical stage company, which engages in the discovery, development, and commercialization of cannabinoid-based products and technologies for the treatment of cancer. Its products include Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome (CACS), and RCC-33, an anti-neoplastic drug candidate under development for Colorectal Cancer (CRC). The company was founded by Eyal Barad on September 15, 2004 and is headquartered in Bethesda, MD.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
